Management
Corporate Alliances
Intellectual property & Patents
Publications
News
Events & Conferences
Location


Intellectual Property & Patents    

Proprietary Technology
  1. MutaGen™: We have developed and patented a new and innovative DME technology, for any protein based product improvement (antibodies for therapy and diagnostics, antigen for in vitro diagnostic application, therapeutic proteins, and industrial enzymes)
  2. MutalBanks: Using our DME technology, we have generated highly diverse human monoclonal antibody libraries. Antibody leads can be isolated from MutalBanks by library screening then matured by MutaGen (improvement of affinity, specificity) for improved functionality.
  3. MilleMab: Our new comprehensive platform includes cloning, humanisation, optimisation and Immunogenicity risk limitation, when starting from a rodent MAb.
  4. CPPI: Cytoplasmic Protein Protein Interaction. Our yeast based screening system is dedicated to protein-protein interaction detection and drug discovery (peptides, intrabodies).


Intellectual Property

MilleGen antibody discovery platform is covered by 5 patents:

  1. MutaGen™ / Molecular Evolution: WO0238756
  2. MutalBanks: WO2007137616
  3. Screening systems: WO2007119165 and WO2007083226
  4. Whole antibody expression: WO2007135515



Click on figure to enlarge